Literature DB >> 11048640

Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock.

C H Cho1, D H Cho, M R Seo, Y S Juhnn.   

Abstract

Electroconvulsive shock (ECS) has been suggested to affect cAMP signaling pathways to exert therapeutic effects. ECS was recently reported to increase the expression of PDE4 isoforms in rat brain, however, these studies were limited to PDE4 family in the cerebral cortex and hippocampus. Thus, for comprehensive understanding of how ECS regulates PDE activity, the present study was performed to determine whether chronic ECS treatment induces differential changes in the expression of all the PDE isoforms in rat brains. We analyzed the mRNA expression of PDE isoforms in the rat hippocampus and striatum using reverse transcription polymerase chain reaction. We found chronic ECS treatment induced differential changes in the expression of PDE isoform 1, 2, 3, 4, 5 and 7 at the rat hippocampus and striatum. In the hippocampus, the expression of PDE1A/B (694%), PDE4A (158%), PDE4B (323 %), and PDE4D (181%) isoforms was increased from the controls, but the expression of PDE2 (62.8%) and PDE7 (37.8%) decreased by chronic ECS treatment. In the striatum, the expression of PDE1A/B (179%), PDE4A (223%), PDE4B (171%), and PDE4D (327%) was increased by chronic ECS treatment with the concomitant decrease in the expression of PDE2 (78.4%) and PDE3A (67.1%). In conclusion, chronic ECS treatment induces differential changes in the expression of most PDE isoforms including PDE1, PDE2, PDE3, PDE4, PDE5, and PDE7 in the rat hippocampus and striatum in an isoform- and brain region-specific manner. Such differential change is suggested to play an important role in regulation of the activity of PDE and cAMP system by ECS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11048640     DOI: 10.1038/emm.2000.19

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  7 in total

Review 1.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression.

Authors:  Michele P Kelly; York-Fong Cheung; Christopher Favilla; Steven J Siegel; Stephen J Kanes; Miles D Houslay; Ted Abel
Journal:  Learn Mem       Date:  2008-01-28       Impact factor: 2.460

3.  Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.

Authors:  Sarah Threlfell; Anthony R West
Journal:  Basal Ganglia       Date:  2013-12-01

Review 4.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

Review 5.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

6.  Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities.

Authors:  Mohammad Asif
Journal:  N Am J Med Sci       Date:  2012-10

7.  Role of phosphodiesterase 5 in synaptic plasticity and memory.

Authors:  Daniela Puzzo; Salvatore Sapienza; Ottavio Arancio; Agostino Palmeri
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.